107 related articles for article (PubMed ID: 24861196)
1. A possible antineoplastic potential of selective, irreversible proteasome inhibitor, carfilzomib on chemically induced hepatocarcinogenesis in rats.
Mansour MA; Aljoufi MA; Al-Hosaini K; Al-Rikabi AC; Nagi MN
J Biochem Mol Toxicol; 2014 Sep; 28(9):400-6. PubMed ID: 24861196
[TBL] [Abstract][Full Text] [Related]
2. Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.
Mansour MA; Aljoufi MA; Al-Hosaini K; Al-Rikabi AC; Nagi MN
Chem Biol Interact; 2014 May; 215():17-24. PubMed ID: 24632418
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Al-Harbi NO
Toxicol Mech Methods; 2016; 26(3):189-95. PubMed ID: 26899300
[TBL] [Abstract][Full Text] [Related]
4. Ginger ingredients inhibit the development of diethylnitrosoamine induced premalignant phenotype in rat chemical hepatocarcinogenesis model.
Mansour MA; Bekheet SA; Al-Rejaie SS; Al-Shabanah OA; Al-Howiriny TA; Al-Rikabi AC; Abdo AA
Biofactors; 2010; 36(6):483-90. PubMed ID: 20872761
[TBL] [Abstract][Full Text] [Related]
5. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib reverses pulmonary arterial hypertension.
Wang X; Ibrahim YF; Das D; Zungu-Edmondson M; Shults NV; Suzuki YJ
Cardiovasc Res; 2016 May; 110(2):188-99. PubMed ID: 26952044
[TBL] [Abstract][Full Text] [Related]
7. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
8. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice.
Alanazi A; Algfeley SG; Al-Hosaini KA; Korashy HM; Imam F; Nagi MN
J Biochem Mol Toxicol; 2017 Apr; 31(4):. PubMed ID: 27900802
[TBL] [Abstract][Full Text] [Related]
10. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
12. Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-κB signaling pathway.
Al-Harbi NO; Imam F; Al-Harbi MM; Al-Shabanah OA; Alotaibi MR; As Sobeai HM; Afzal M; Kazmi I; Al Rikabi AC
Inflammopharmacology; 2019 Aug; 27(4):817-827. PubMed ID: 30600471
[TBL] [Abstract][Full Text] [Related]
13. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
14. Effect of two selenium sources on hepatocarcinogenesis and several angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats.
Liu JG; Zhao HJ; Liu YJ; Liu YW; Wang XL
J Trace Elem Med Biol; 2012 Oct; 26(4):255-61. PubMed ID: 22425635
[TBL] [Abstract][Full Text] [Related]
15. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
16. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
17. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats.
Ramakrishnan G; Raghavendran HR; Vinodhkumar R; Devaki T
Chem Biol Interact; 2006 Jun; 161(2):104-14. PubMed ID: 16643877
[TBL] [Abstract][Full Text] [Related]
18. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitizing effect of Alpinia officinarum rhizome extract in cisplatin-treated rats with hepatocellular carcinoma.
Abass SA; Abdel-Hamid NM; Abouzed TK; El-Shishtawy MM
Biomed Pharmacother; 2018 May; 101():710-718. PubMed ID: 29524879
[TBL] [Abstract][Full Text] [Related]
20. Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.
Chen-Scarabelli C; Corsetti G; Pasini E; Dioguardi FS; Sahni G; Narula J; Gavazzoni M; Patel H; Saravolatz L; Knight R; Raddino R; Scarabelli TM
EBioMedicine; 2017 Jul; 21():206-212. PubMed ID: 28587834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
